Fractyl Health, Inc.
- GUTS
- NASDAQ
- Biotechnology
- Metabolic Therapeutics
- Obesity/Diabetes (Revita)
$1.33
Today −3.62%Quote Oct 20, 2026, 08:00 PM UTC
−80.61%over the last month
Max drawdown −80.6%From 1-month high −80.6%3 months −85.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
100
Founded
2010
Market value
$211.7M
Quote Oct 20
Analyst target
$5.00
+275.9% from here
Floor
$0.53
60.4% below price
Resistance
$2.55
92.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GUTSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free